EC Opens Investigation on J&J (JNJ) Over Fentanyl Patches (NVS)
Tweet
Share
E-mailGet Alerts JNJ Hot Sheet
Join SI Premium – FREE
According to reports Friday, Johnson & Johnson (NYSE: JNJ) affirmed it is being investigated by the European Commission. The company said it is fully cooperating with authorities.
One spokesperson for Johnson & Johnson said, "We confirm that the European Commission has initiated an investigation against Janssen-Cilag BV (Netherlands) and its parent company Johnson & Johnson...the commission has not made any definitive finding that Janssen-Cilag BV has infringed competition rules."
Johnson & Johnson noted the investigation focuses on contractual arrangements with Novartis' (NYSE: NVS) units Hexal/Sandoz concerning fentanyl patches in the Netherlands in the period from 2005 to 2006.
Headlines first leaked from Dow Jones.
One spokesperson for Johnson & Johnson said, "We confirm that the European Commission has initiated an investigation against Janssen-Cilag BV (Netherlands) and its parent company Johnson & Johnson...the commission has not made any definitive finding that Janssen-Cilag BV has infringed competition rules."
Johnson & Johnson noted the investigation focuses on contractual arrangements with Novartis' (NYSE: NVS) units Hexal/Sandoz concerning fentanyl patches in the Netherlands in the period from 2005 to 2006.
Headlines first leaked from Dow Jones.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
- Gray Media closes $750M note offering to refinance higher-rate debt
- Alzamend Neuro (ALZN) files for 98.4M share offering by selling stockholders
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
